Skip to main content
. 2012 Mar;14(3):249–258. doi: 10.1593/neo.111498

Figure 4.

Figure 4

PKC pathway activation mediates survival of metastatic cancer cells. (A) The relevant target modulation of each pathway (Akt, mTOR, PKC, Src, and MAPK) inhibitor at the exposures that do not influence cell proliferation was confirmed by Western analysis. (B) PuMA cultures (K7M2 cells) were treated with pathway inhibitors or DX-52-1 as a positive control (+ Cont) compared to untreated cells (− Cont). PuMA metastatic burden was significantly lower in PKC inhibitor-treated group. Fluorescent cells (white arrows) have been confirmed as tumor cells by hematoxylin and eosin staining of lung sections in the PuMA (data not shown). Scale bar, 400 µm. (C) Pulmonary metastasis survival index was calculated by dividing the tumor burden (area of fluorescence) in the inhibitor-treated lung section by that of control-treated lung section. PKC-and DX-52-1-treated metastatic tumor burden was significantly lower than the control group (*P < .01). All data represent the mean values ± SD from experiments performed at least three times; one-way ANOVA.